tetano
Editor, Senior Moderator
J Mol Diagn
. 2020 Oct 26;S1525-1578(20)30522-5.
doi: 10.1016/j.jmoldx.2020.10.008. Online ahead of print.
External Quality Assessment for Molecular Detection of Severe Acute Respiratory Syndrome Coronavirus 2 in Clinical laboratories
Zhe Wang[SUP] 1 [/SUP], Yuqing Chen[SUP] 1 [/SUP], Jing Yang[SUP] 1 [/SUP], Yanxi Han[SUP] 2 [/SUP], Jiping Shi[SUP] 3 [/SUP], Shaohua Zhan[SUP] 1 [/SUP], Rongxue Peng[SUP] 2 [/SUP], Rui Li[SUP] 1 [/SUP], Runling Zhang[SUP] 1 [/SUP], Jinming Li[SUP] 4 [/SUP], Rui Zhang[SUP] 5 [/SUP]
Affiliations
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a huge threat to public health. Viral nucleic acid testing is the diagnostic gold standard and can play an important role in the prevention and control of this infection. In this study, bacteriophage MS2 virus-like particles encapsulating specific RNA sequences of SARS-CoV-2 and other coronaviruses were prepared by genetic engineering. The assessment panel, consisting of four positive samples with concentrations of 2.8, 3.5, 4.2 and 4.9 log[SUB]10[/SUB] copies/mL and five negative samples with other human coronaviruses, was prepared and distributed to evaluate the accuracy of routine viral RNA detection. Results of 931 panels from 844 laboratories were collected. The overall percent agreement (OPA), positive percent agreement (PPA) and negative percent agreement (NPA), defined as the percentage of agreement between the correct results and total results submitted for all, positive and negative samples were 96.8% (8109/8379), 93.9% (3497/3724), and 99.1% (4612/4655), respectively. For samples with concentrations of 4.9 and 4.2 log[SUB]10[/SUB] copies/mL, the PPAs were > 95%. However, for 3.5 and 2.8 log[SUB]10[/SUB] copies/mL, the PPAs were 94.6% (881/931) and 84.9% (790/931), respectively. For all negative samples, the NPAs were > 95%. Thus, the majority of laboratories can reliably detect SARS-CoV-2. However, further improvement and optimization is required to ensure the accuracy of detection in panel members with lower concentrations of viral RNA.
. 2020 Oct 26;S1525-1578(20)30522-5.
doi: 10.1016/j.jmoldx.2020.10.008. Online ahead of print.
External Quality Assessment for Molecular Detection of Severe Acute Respiratory Syndrome Coronavirus 2 in Clinical laboratories
Zhe Wang[SUP] 1 [/SUP], Yuqing Chen[SUP] 1 [/SUP], Jing Yang[SUP] 1 [/SUP], Yanxi Han[SUP] 2 [/SUP], Jiping Shi[SUP] 3 [/SUP], Shaohua Zhan[SUP] 1 [/SUP], Rongxue Peng[SUP] 2 [/SUP], Rui Li[SUP] 1 [/SUP], Runling Zhang[SUP] 1 [/SUP], Jinming Li[SUP] 4 [/SUP], Rui Zhang[SUP] 5 [/SUP]
Affiliations
- PMID: 33122140
- DOI: 10.1016/j.jmoldx.2020.10.008
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a huge threat to public health. Viral nucleic acid testing is the diagnostic gold standard and can play an important role in the prevention and control of this infection. In this study, bacteriophage MS2 virus-like particles encapsulating specific RNA sequences of SARS-CoV-2 and other coronaviruses were prepared by genetic engineering. The assessment panel, consisting of four positive samples with concentrations of 2.8, 3.5, 4.2 and 4.9 log[SUB]10[/SUB] copies/mL and five negative samples with other human coronaviruses, was prepared and distributed to evaluate the accuracy of routine viral RNA detection. Results of 931 panels from 844 laboratories were collected. The overall percent agreement (OPA), positive percent agreement (PPA) and negative percent agreement (NPA), defined as the percentage of agreement between the correct results and total results submitted for all, positive and negative samples were 96.8% (8109/8379), 93.9% (3497/3724), and 99.1% (4612/4655), respectively. For samples with concentrations of 4.9 and 4.2 log[SUB]10[/SUB] copies/mL, the PPAs were > 95%. However, for 3.5 and 2.8 log[SUB]10[/SUB] copies/mL, the PPAs were 94.6% (881/931) and 84.9% (790/931), respectively. For all negative samples, the NPAs were > 95%. Thus, the majority of laboratories can reliably detect SARS-CoV-2. However, further improvement and optimization is required to ensure the accuracy of detection in panel members with lower concentrations of viral RNA.